Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) EBIT (2016 - 2026)

Protara Therapeutics' EBIT history spans 14 years, with the latest figure at -$19.6 million for Q1 2026.

  • Quarterly EBIT fell 38.98% to -$19.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$70.1 million through Mar 2026, down 36.22% year-over-year, with the annual reading at -$64.5 million for FY2025, 31.32% down from the prior year.
  • EBIT came in at -$19.6 million for Q1 2026, down from -$19.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$8.0 million in Q3 2022 to a low of -$39.5 million in Q4 2022.
  • The 5-year median for EBIT is -$12.1 million (2023), against an average of -$14.4 million.
  • Year-over-year, EBIT tumbled 284.07% in 2022 and then skyrocketed 72.05% in 2023.
  • Protara Therapeutics' EBIT stood at -$39.5 million in 2022, then surged by 72.05% to -$11.0 million in 2023, then decreased by 29.63% to -$14.3 million in 2024, then crashed by 33.31% to -$19.1 million in 2025, then dropped by 2.88% to -$19.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's EBIT are -$19.6 million (Q1 2026), -$19.1 million (Q4 2025), and -$14.8 million (Q3 2025).